Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:UCB,_Inc.
|
| gptkbp:activities |
stimulates dopamine receptors
|
| gptkbp:class |
dopamine agonist
|
| gptkbp:clinical_trial |
symptomatic treatment
improving quality of life Phase III trials long-term management |
| gptkbp:contraindication |
severe liver impairment
concurrent use of certain medications hypersensitivity to rotigotine |
| gptkbp:dosage_form |
gptkb:spacecraft
|
| gptkbp:effective_date |
gptkb:2007
|
| gptkbp:form |
gptkb:spacecraft
|
| gptkbp:has_ability |
10 mg/24 hours
2 mg/24 hours 4 mg/24 hours 6 mg/24 hours 8 mg/24 hours 12 mg/24 hours 16 mg/24 hours 24 mg/24 hours |
| https://www.w3.org/2000/01/rdf-schema#label |
Neupro
|
| gptkbp:ingredients |
rotigotine
|
| gptkbp:interacts_with |
antidepressants
antipsychotics antiemetics other dopamine agonists |
| gptkbp:is_used_for |
gptkb:psychologist
gptkb:restless_legs_syndrome |
| gptkbp:manager |
transdermal
|
| gptkbp:manufacturer |
UCBS. A.
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:Australia gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:packaging |
single-use patches
|
| gptkbp:requires |
prescription only
|
| gptkbp:research_focus |
Parkinson's disease treatment
restless legs syndrome treatment dopamine receptor activity |
| gptkbp:scholarships |
avoid alcohol
do not stop abruptly monitor for unusual urges report any skin reactions |
| gptkbp:side_effect |
dizziness
headache nausea vomiting insomnia skin reactions somnolence |
| gptkbp:storage |
room temperature
protected from light |